Crispr Therapeutics AG is trading at $51.24 (10.0% down) as a stronger-than-expected U.S. jobs report pressures rate-sensitive growth stocks and prompts widespread profit-taking.
- The decline sharply reverses a portion of the stock's recent rally following a significant gain on June 4.
- The move is driven by a broad, risk-off sentiment affecting the tech and growth sectors rather than any new company-specific developments.
- Higher-than-anticipated employment data is weighing on biotech valuations as investors recalibrate expectations for the interest rate environment.